Opinion

Video

Safety and Efficacy of Janus Kinase Inhibitors

Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.

Video content above is prompted by the following:

Results from the 2021 ORAL Surveillance study showed the Janus kinase inhibitor (JAKi) tofacitinib was associated with a cardiovascular and cancer risk.

  • Can you describe concerns and misperceptions that ensued from results of the ORAL Surveillance study? What were the limitations of the study?
  • Can you please share how you weigh JAKi safety concerns with their efficacy outcomes?
  • In your clinical observations, what role have JAKis played in helping patients with rheumatoid arthritis achieve remission?
Related Videos
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
A panel of 3 experts on atopic dermatitis
© 2024 MJH Life Sciences

All rights reserved.